Bristol‑Myers Squibb received U.S. Food and Drug Administration approval for its combination of Opdivo (nivolumab) and AVD chemotherapy for adults and adolescents aged 12 and older with previously untreated Stage III or IV classical Hodgkin lymphoma, adding a high‑margin indication to the company’s oncology portfolio.
The approval was based on the CA209‑8UT (SWOG 1826) Phase 3 trial, which showed a hazard ratio of 0.42 for progression‑free survival and a median PFS that was not reached after a median follow‑up of 13.7 months, underscoring the clinical benefit of the new regimen.
Strategically, the approval strengthens BMY’s Growth Portfolio and positions the company to compete more aggressively with Merck’s Keytruda and Pfizer’s oncology offerings. The new indication is expected to generate significant revenue and reinforce the company’s focus on high‑margin therapies.
Financially, BMY’s Q4 2025 results were strong: total revenue reached $12.5 billion and non‑GAAP EPS was $1.26, beating consensus estimates. The company guided 2026 revenue to $46.0‑$47.5 billion and non‑GAAP EPS to $6.05‑$6.35, reflecting confidence in continued growth. Growth Portfolio revenue rose 16% in Q4 2025, while non‑GAAP gross margin fell from 74.0% to 71.9% due to a product‑mix shift. Research and development expenses were 8% lower on a non‑GAAP basis, driven by a strategic productivity initiative.
CEO Christopher Boerner said, "We made significant progress in 2025, with real momentum in our Growth Portfolio and a strengthened balance sheet that provides the strategic flexibility to continue investing in growth drivers. 2026 is data‑rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year. Our core business is strong and growing, and we have the potential to achieve industry‑leading, sustainable growth into the 2030s and beyond."
The approval is expected to add significant revenue to BMY’s oncology segment and further solidify its competitive position in a market where high‑margin immuno‑oncology therapies are in high demand. The company’s focus on expanding its Growth Portfolio, combined with the new indication, positions BMY to capitalize on unmet needs in Hodgkin lymphoma while maintaining momentum in its broader oncology pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.